Skip to main content
Heart logoLink to Heart
. 2000 Jul;84(1):14–24. doi: 10.1136/heart.84.1.14

Antiarrhythmics—from cell to clinic: past, present, and future

J Hancox 1, K Patel 1, J Jones 1
PMCID: PMC1729402  PMID: 10862579

Full Text

The Full Text of this article is available as a PDF (235.7 KB).

Figure 1  .

Figure 1  

Schematic illustration of representative action potentials from (A) cardiac pacemaker cell, (B) ventricular cell, and (C) atrial cell.

Figure 2  .

Figure 2  

Ionic and membrane potential gradients determine the direction of ion flow across the cell membrane. (A) Direction of sodium movement (shown by arrow) with normal transmembrane Na gradient. Reversal/equilibrium potential (ENa) is calculated using the Nernst equation (left panel inset shows this for Na at physiological temperature). When transmembrane potential (VM) is less positive than ENa the electrochemical gradient favours Na entry (left panel). Right panel: If VM exceeds ENa (for example, by depolarising the cell beyond ENa—illustrated by +++), the electrochemical gradient favours sodium exit. (B) Direction of potassium movement (shown by arrow) with normal transmembrane K gradient when VM is more positive than EK (left panel) and more negative than EK (right panel; - - - represents applied hyperpolarisation).

Figure 3  .

Figure 3  

(A) Ion channels undergo changes in protein conformation that determine whether ionic current flows or not. At rest channels are closed (C), but when an appropriate stimulus is applied (a change in membrane potential for voltage operated channels, an appropriate ligand, for example, acetylcholine, for ligand operated channels), the channel conformation changes (during a process called "activation"; C→O) to allow the relevant ion to pass through the channel pore, here shown for ions passing from inside to outside of the cell. Many voltage operated channels undergo a second transition; in the presence of a sustained depolarising stimulus, the channel conformation undergoes a further change to prevent current flow—this process is called inactivation (O→I). Inactivation can occur in two ways; either a blocking particle moves to occlude the internal face of the channel pore (N type inactivation), or a change to the outer portion of the channel pore prevents ion flow (C type inactivation). The net result is that ions can no longer pass through the channel pore. (B) Measurements of ionic current from heart cells are made using voltage or patch clamp methods. These techniques allow detailed study of drug-channel interactions. To introduce ionic current records to the reader unfamiliar with this technique, we present example currents, recorded from an individual ventricular myocyte using whole cell patch clamp. The membrane potential is controlled by the experimenter, allowing measurements of whole cell membrane current to be made in response to applied voltage commands. In this example, the cell membrane potential is held at -80 mV and a double step pulse applied. The first step to −40 mV elicits a large and brief downward current deflection. This represents a large, rapidly activating and inactivating current through Na channels. The second step to +10 mV elicits a second downward deflection (of smaller amplitude than INa), which then gradually returns to baseline during the command step. This represents current flow through L type Ca channels and shows that ICa,L activates quickly, and then subsequently inactivates (at a slower rate than inactivation of INa). Both ICa,L and INa are inward or depolarising currents. A current deflection in the opposite direction (with an amplitude positive to 0 on the current axis) would represent an outward, or repolarising current.

Selected References

These references are in PubMed. This may not be the complete list of references from this article.

  1. Antzelevitch C. The Brugada syndrome. J Cardiovasc Electrophysiol. 1998 May;9(5):513–516. doi: 10.1111/j.1540-8167.1998.tb01844.x. [DOI] [PubMed] [Google Scholar]
  2. Balser J. R., Bennett P. B., Hondeghem L. M., Roden D. M. Suppression of time-dependent outward current in guinea pig ventricular myocytes. Actions of quinidine and amiodarone. Circ Res. 1991 Aug;69(2):519–529. doi: 10.1161/01.res.69.2.519. [DOI] [PubMed] [Google Scholar]
  3. Bargheer K., Bode F., Klein H. U., Trappe H. J., Franz M. R., Lichtlen P. R. Prolongation of monophasic action potential duration and the refractory period in the human heart by tedisamil, a new potassium-blocking agent. Eur Heart J. 1994 Oct;15(10):1409–1414. doi: 10.1093/oxfordjournals.eurheartj.a060403. [DOI] [PubMed] [Google Scholar]
  4. Bashir Y., Thomsen P. E., Kingma J. H., Møller M., Wong C., Cobbe S. M., Jordaens L., Campbell R. W., Rasmussen H. S., Camm A. J. Electrophysiologic profile and efficacy of intravenous dofetilide (UK-68,798), a new class III antiarrhythmic drug, in patients with sustained monomorphic ventricular tachycardia. Dofetilide Arrhythmia Study Group. Am J Cardiol. 1995 Nov 15;76(14):1040–1044. doi: 10.1016/s0002-9149(99)80293-8. [DOI] [PubMed] [Google Scholar]
  5. Belardinelli L., Giles W. R., West A. Ionic mechanisms of adenosine actions in pacemaker cells from rabbit heart. J Physiol. 1988 Nov;405:615–633. doi: 10.1113/jphysiol.1988.sp017352. [DOI] [PMC free article] [PubMed] [Google Scholar]
  6. Bennett P. B., Yazawa K., Makita N., George A. L., Jr Molecular mechanism for an inherited cardiac arrhythmia. Nature. 1995 Aug 24;376(6542):683–685. doi: 10.1038/376683a0. [DOI] [PubMed] [Google Scholar]
  7. Boyden P. A., Jeck C. D. Ion channel function in disease. Cardiovasc Res. 1995 Mar;29(3):312–318. [PubMed] [Google Scholar]
  8. Brugada P., Brugada J. Right bundle branch block, persistent ST segment elevation and sudden cardiac death: a distinct clinical and electrocardiographic syndrome. A multicenter report. J Am Coll Cardiol. 1992 Nov 15;20(6):1391–1396. doi: 10.1016/0735-1097(92)90253-j. [DOI] [PubMed] [Google Scholar]
  9. Camm A. J., Yap Y. G. What should we expect from the next generation of antiarrhythmic drugs? J Cardiovasc Electrophysiol. 1999 Feb;10(2):307–317. doi: 10.1111/j.1540-8167.1999.tb00676.x. [DOI] [PubMed] [Google Scholar]
  10. Campbell T. J. Kinetics of onset of rate-dependent effects of Class I antiarrhythmic drugs are important in determining their effects on refractoriness in guinea-pig ventricle, and provide a theoretical basis for their subclassification. Cardiovasc Res. 1983 Jun;17(6):344–352. doi: 10.1093/cvr/17.6.344. [DOI] [PubMed] [Google Scholar]
  11. Campbell T. J. Resting and rate-dependent depression of maximum rate of depolarisation (Vmax) in guinea pig ventricular action potentials by mexiletine, disopyramide, and encainide. J Cardiovasc Pharmacol. 1983 Mar-Apr;5(2):291–296. doi: 10.1097/00005344-198303000-00021. [DOI] [PubMed] [Google Scholar]
  12. Campbell T. J., Vaughan Williams E. M. Voltage- and time-dependent depression of maximum rate of depolarisation of guinea-pig ventricular action potentials by two new antiarrhythmic drugs, flecainide and lorcainide. Cardiovasc Res. 1983 May;17(5):251–258. doi: 10.1093/cvr/17.5.251. [DOI] [PubMed] [Google Scholar]
  13. Cardinal R., Janse M. J., van Eeden I., Werner G., d'Alnoncourt C. N., Durrer D. The effects of lidocaine on intracellular and extracellular potentials, activation, and ventricular arrhythmias during acute regional ischemia in the isolated porcine heart. Circ Res. 1981 Sep;49(3):792–806. doi: 10.1161/01.res.49.3.792. [DOI] [PubMed] [Google Scholar]
  14. Carmeliet E. K+ channels and control of ventricular repolarization in the heart. Fundam Clin Pharmacol. 1993;7(1):19–28. doi: 10.1111/j.1472-8206.1993.tb00214.x. [DOI] [PubMed] [Google Scholar]
  15. Carmeliet E. Mechanisms and control of repolarization. Eur Heart J. 1993 Nov;14 (Suppl H):3–13. doi: 10.1093/eurheartj/14.suppl_h.3. [DOI] [PubMed] [Google Scholar]
  16. Carmeliet E. Use-dependent block and use-dependent unblock of the delayed rectifier K+ current by almokalant in rabbit ventricular myocytes. Circ Res. 1993 Nov;73(5):857–868. doi: 10.1161/01.res.73.5.857. [DOI] [PubMed] [Google Scholar]
  17. Carmeliet E. Use-dependent block of the delayed K+ current in rabbit ventricular myocytes. Cardiovasc Drugs Ther. 1993 Aug;7 (Suppl 3):599–604. doi: 10.1007/BF00877626. [DOI] [PubMed] [Google Scholar]
  18. Chen Q., Kirsch G. E., Zhang D., Brugada R., Brugada J., Brugada P., Potenza D., Moya A., Borggrefe M., Breithardt G. Genetic basis and molecular mechanism for idiopathic ventricular fibrillation. Nature. 1998 Mar 19;392(6673):293–296. doi: 10.1038/32675. [DOI] [PubMed] [Google Scholar]
  19. Chi L., Park J. L., Friedrichs G. S., Banglawala Y. A., Perez M. A., Tanhehco E. J., Lucchesi B. R. Effects of tedisamil (KC-8857) on cardiac electrophysiology and ventricular fibrillation in the rabbit isolated heart. Br J Pharmacol. 1996 Mar;117(6):1261–1269. doi: 10.1111/j.1476-5381.1996.tb16724.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  20. Choi H. S., Eisner D. A. The role of sarcolemmal Ca2+-ATPase in the regulation of resting calcium concentration in rat ventricular myocytes. J Physiol. 1999 Feb 15;515(Pt 1):109–118. doi: 10.1111/j.1469-7793.1999.109ad.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  21. Clozel J. P., Ertel E. A., Ertel S. I. Discovery and main pharmacological properties of mibefradil (Ro 40-5967), the first selective T-type calcium channel blocker. J Hypertens Suppl. 1997 Dec;15(5):S17–S25. doi: 10.1097/00004872-199715055-00004. [DOI] [PubMed] [Google Scholar]
  22. Compton S. J., Lux R. L., Ramsey M. R., Strelich K. R., Sanguinetti M. C., Green L. S., Keating M. T., Mason J. W. Genetically defined therapy of inherited long-QT syndrome. Correction of abnormal repolarization by potassium. Circulation. 1996 Sep 1;94(5):1018–1022. doi: 10.1161/01.cir.94.5.1018. [DOI] [PubMed] [Google Scholar]
  23. Dumaine R., Wang Q., Keating M. T., Hartmann H. A., Schwartz P. J., Brown A. M., Kirsch G. E. Multiple mechanisms of Na+ channel--linked long-QT syndrome. Circ Res. 1996 May;78(5):916–924. doi: 10.1161/01.res.78.5.916. [DOI] [PubMed] [Google Scholar]
  24. Flaker G. C., Blackshear J. L., McBride R., Kronmal R. A., Halperin J. L., Hart R. G. Antiarrhythmic drug therapy and cardiac mortality in atrial fibrillation. The Stroke Prevention in Atrial Fibrillation Investigators. J Am Coll Cardiol. 1992 Sep;20(3):527–532. doi: 10.1016/0735-1097(92)90003-6. [DOI] [PubMed] [Google Scholar]
  25. Frishman W. H., Gabor R., Pepine C., Cavusoglu E. Heart rate reduction in the treatment of chronic stable angina pectoris: experiences with a sinus node inhibitor. Am Heart J. 1996 Jan;131(1):204–210. doi: 10.1016/s0002-8703(96)90075-7. [DOI] [PubMed] [Google Scholar]
  26. Funck-Brentano C. Rate-dependence of class III actions in the heart. Fundam Clin Pharmacol. 1993;7(1):51–59. doi: 10.1111/j.1472-8206.1993.tb00217.x. [DOI] [PubMed] [Google Scholar]
  27. Gadsby D. C. The Na/K pump of cardiac cells. Annu Rev Biophys Bioeng. 1984;13:373–398. doi: 10.1146/annurev.bb.13.060184.002105. [DOI] [PubMed] [Google Scholar]
  28. Gintant G. A. Azimilide causes reverse rate-dependent block while reducing both components of delayed-rectifier current in canine ventricular myocytes. J Cardiovasc Pharmacol. 1998 Jun;31(6):945–953. doi: 10.1097/00005344-199806000-00020. [DOI] [PubMed] [Google Scholar]
  29. Goy J. J., Fromer M. Antiarrhythmic treatment of atrioventricular tachycardias. J Cardiovasc Pharmacol. 1991;17 (Suppl 6):S36–S40. [PubMed] [Google Scholar]
  30. Grace A. A. Brugada syndrome. Lancet. 1999 Aug 7;354(9177):445–446. doi: 10.1016/S0140-6736(99)90032-6. [DOI] [PubMed] [Google Scholar]
  31. Grant A. O., John J. E., Nesterenko V. V., Starmer C. F., Moorman J. R. The role of inactivation in open-channel block of the sodium channel: studies with inactivation-deficient mutant channels. Mol Pharmacol. 1996 Dec;50(6):1643–1650. [PubMed] [Google Scholar]
  32. Grant A. O. Mechanisms of action of antiarrhythmic drugs: from ion channel blockage to arrhythmia termination. Pacing Clin Electrophysiol. 1997 Feb;20(2 Pt 2):432–444. doi: 10.1111/j.1540-8159.1997.tb06202.x. [DOI] [PubMed] [Google Scholar]
  33. Groh W. J., Gibson K. J., Maylie J. G. Comparison of the rate-dependent properties of the class III antiarrhythmic agents azimilide (NE-10064) and E-4031: considerations on the mechanism of reverse rate-dependent action potential prolongation. J Cardiovasc Electrophysiol. 1997 May;8(5):529–536. doi: 10.1111/j.1540-8167.1997.tb00821.x. [DOI] [PubMed] [Google Scholar]
  34. Hancox J. C., Mitcheson J. S. Ion channel and exchange currents in single myocytes isolated from the rabbit atrioventricular node. Can J Cardiol. 1997 Dec;13(12):1175–1182. [PubMed] [Google Scholar]
  35. Hille B. Local anesthetics: hydrophilic and hydrophobic pathways for the drug-receptor reaction. J Gen Physiol. 1977 Apr;69(4):497–515. doi: 10.1085/jgp.69.4.497. [DOI] [PMC free article] [PubMed] [Google Scholar]
  36. Hondeghem L. M., Katzung B. G. Time- and voltage-dependent interactions of antiarrhythmic drugs with cardiac sodium channels. Biochim Biophys Acta. 1977 Nov 14;472(3-4):373–398. doi: 10.1016/0304-4157(77)90003-x. [DOI] [PubMed] [Google Scholar]
  37. Hondeghem L. M., Matsubara T. Quinidine blocks cardiac sodium channels during opening and slow inactivation in guinea-pig papillary muscle. Br J Pharmacol. 1988 Feb;93(2):311–318. doi: 10.1111/j.1476-5381.1988.tb11436.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  38. Hondeghem L. M., Snyders D. J. Class III antiarrhythmic agents have a lot of potential but a long way to go. Reduced effectiveness and dangers of reverse use dependence. Circulation. 1990 Feb;81(2):686–690. doi: 10.1161/01.cir.81.2.686. [DOI] [PubMed] [Google Scholar]
  39. Irisawa H., Brown H. F., Giles W. Cardiac pacemaking in the sinoatrial node. Physiol Rev. 1993 Jan;73(1):197–227. doi: 10.1152/physrev.1993.73.1.197. [DOI] [PubMed] [Google Scholar]
  40. JERVELL A., LANGE-NIELSEN F. Congenital deaf-mutism, functional heart disease with prolongation of the Q-T interval and sudden death. Am Heart J. 1957 Jul;54(1):59–68. doi: 10.1016/0002-8703(57)90079-0. [DOI] [PubMed] [Google Scholar]
  41. January C. T., Riddle J. M. Early afterdepolarizations: mechanism of induction and block. A role for L-type Ca2+ current. Circ Res. 1989 May;64(5):977–990. doi: 10.1161/01.res.64.5.977. [DOI] [PubMed] [Google Scholar]
  42. Janvier N. C., Boyett M. R. The role of Na-Ca exchange current in the cardiac action potential. Cardiovasc Res. 1996 Jul;32(1):69–84. [PubMed] [Google Scholar]
  43. Jurkiewicz N. K., Sanguinetti M. C. Rate-dependent prolongation of cardiac action potentials by a methanesulfonanilide class III antiarrhythmic agent. Specific block of rapidly activating delayed rectifier K+ current by dofetilide. Circ Res. 1993 Jan;72(1):75–83. doi: 10.1161/01.res.72.1.75. [DOI] [PubMed] [Google Scholar]
  44. Klein H. O., Pauzner H., Di Segni E., David D., Kaplinsky E. The beneficial effects of verapamil in chronic atrial fibrillation. Arch Intern Med. 1979 Jul;139(7):747–749. [PubMed] [Google Scholar]
  45. Kohlhardt M., Fichtner H. Block of single cardiac Na+ channels by antiarrhythmic drugs: the effect of amiodarone, propafenone and diprafenone. J Membr Biol. 1988 May;102(2):105–119. doi: 10.1007/BF01870449. [DOI] [PubMed] [Google Scholar]
  46. Lai L., Su M., Tseng Y., Lien W. Sensitivity of the slow component of the delayed rectifier potassium current (IKs) to potassium channel blockers: implications for clinical reverse use-dependent effects. J Biomed Sci. 1999 Jul-Aug;6(4):251–259. doi: 10.1007/BF02253566. [DOI] [PubMed] [Google Scholar]
  47. Lima J. J., Boudoulas H. Stereoselective effects of disopyramide enantiomers in humans. J Cardiovasc Pharmacol. 1987 May;9(5):594–600. doi: 10.1097/00005344-198705000-00014. [DOI] [PubMed] [Google Scholar]
  48. MARK L. C., KAYDEN H. J., STEELE J. M., COOPER J. R., BERLIN I., ROVENSTINE E. A., BRODIE B. B. The physiological disposition and cardiac effects of procaine amide. J Pharmacol Exp Ther. 1951 May;102(1):5–15. [PubMed] [Google Scholar]
  49. Marschang H., Beyer T., Karolyi L., Kübler W., Brachmann J. Differential rate and potassium-dependent effects of the class III agents d-sotalol and dofetilide on guinea pig papillary muscle. Cardiovasc Drugs Ther. 1998 Dec;12(6):573–583. doi: 10.1023/a:1007743521932. [DOI] [PubMed] [Google Scholar]
  50. Martynyuk A. E., Kane K. A., Cobbe S. M., Rankin A. C. Adenosine increases potassium conductance in isolated rabbit atrioventricular nodal myocytes. Cardiovasc Res. 1995 Nov;30(5):668–675. [PubMed] [Google Scholar]
  51. Nattel S., Hadjis T., Talajic M. The treatment of atrial fibrillation. An evaluation of drug therapy, electrical modalities and therapeutic considerations. Drugs. 1994 Sep;48(3):345–371. doi: 10.2165/00003495-199448030-00003. [DOI] [PubMed] [Google Scholar]
  52. Nattel S., Liu L., St-Georges D. Effects of the novel antiarrhythmic agent azimilide on experimental atrial fibrillation and atrial electrophysiologic properties. Cardiovasc Res. 1998 Mar;37(3):627–635. doi: 10.1016/s0008-6363(97)00252-6. [DOI] [PubMed] [Google Scholar]
  53. Nishimura M., Habuchi Y., Hiromasa S., Watanabe Y. Ionic basis of depressed automaticity and conduction by acetylcholine in rabbit AV node. Am J Physiol. 1988 Jul;255(1 Pt 2):H7–14. doi: 10.1152/ajpheart.1988.255.1.H7. [DOI] [PubMed] [Google Scholar]
  54. Nitta J., Sunami A., Marumo F., Hiraoka M. States and sites of actions of flecainide on guinea-pig cardiac sodium channels. Eur J Pharmacol. 1992 Apr 22;214(2-3):191–197. doi: 10.1016/0014-2999(92)90118-n. [DOI] [PubMed] [Google Scholar]
  55. Po S. S., Wang D. W., Yang I. C., Johnson J. P., Jr, Nie L., Bennett P. B. Modulation of HERG potassium channels by extracellular magnesium and quinidine. J Cardiovasc Pharmacol. 1999 Feb;33(2):181–185. doi: 10.1097/00005344-199902000-00002. [DOI] [PubMed] [Google Scholar]
  56. Priori S. G., Barhanin J., Hauer R. N., Haverkamp W., Jongsma H. J., Kleber A. G., McKenna W. J., Roden D. M., Rudy Y., Schwartz K. Genetic and molecular basis of cardiac arrhythmias; impact on clinical management. Study group on molecular basis of arrhythmias of the working group on arrhythmias of the european society of cardiology. Eur Heart J. 1999 Feb;20(3):174–195. doi: 10.1053/euhj.1998.1220. [DOI] [PubMed] [Google Scholar]
  57. Ragsdale D. S., McPhee J. C., Scheuer T., Catterall W. A. Common molecular determinants of local anesthetic, antiarrhythmic, and anticonvulsant block of voltage-gated Na+ channels. Proc Natl Acad Sci U S A. 1996 Aug 20;93(17):9270–9275. doi: 10.1073/pnas.93.17.9270. [DOI] [PMC free article] [PubMed] [Google Scholar]
  58. Reiffen M., Eberlein W., Müller P., Psiorz M., Noll K., Heider J., Lillie C., Kobinger W., Luger P. Specific bradycardic agents. 1. Chemistry, pharmacology, and structure-activity relationships of substituted benzazepinones, a-new class of compounds exerting antiischemic properties. J Med Chem. 1990 May;33(5):1496–1504. doi: 10.1021/jm00167a033. [DOI] [PubMed] [Google Scholar]
  59. Roden D. M., Bennett P. B., Snyders D. J., Balser J. R., Hondeghem L. M. Quinidine delays IK activation in guinea pig ventricular myocytes. Circ Res. 1988 May;62(5):1055–1058. doi: 10.1161/01.res.62.5.1055. [DOI] [PubMed] [Google Scholar]
  60. Roden D. M., Lazzara R., Rosen M., Schwartz P. J., Towbin J., Vincent G. M. Multiple mechanisms in the long-QT syndrome. Current knowledge, gaps, and future directions. The SADS Foundation Task Force on LQTS. Circulation. 1996 Oct 15;94(8):1996–2012. doi: 10.1161/01.cir.94.8.1996. [DOI] [PubMed] [Google Scholar]
  61. Sanguinetti M. C., Curran M. E., Spector P. S., Keating M. T. Spectrum of HERG K+-channel dysfunction in an inherited cardiac arrhythmia. Proc Natl Acad Sci U S A. 1996 Mar 5;93(5):2208–2212. doi: 10.1073/pnas.93.5.2208. [DOI] [PMC free article] [PubMed] [Google Scholar]
  62. Sanguinetti M. C., Curran M. E., Zou A., Shen J., Spector P. S., Atkinson D. L., Keating M. T. Coassembly of K(V)LQT1 and minK (IsK) proteins to form cardiac I(Ks) potassium channel. Nature. 1996 Nov 7;384(6604):80–83. doi: 10.1038/384080a0. [DOI] [PubMed] [Google Scholar]
  63. Sanguinetti M. C., Jiang C., Curran M. E., Keating M. T. A mechanistic link between an inherited and an acquired cardiac arrhythmia: HERG encodes the IKr potassium channel. Cell. 1995 Apr 21;81(2):299–307. doi: 10.1016/0092-8674(95)90340-2. [DOI] [PubMed] [Google Scholar]
  64. Sanguinetti M. C., Jurkiewicz N. K. Two components of cardiac delayed rectifier K+ current. Differential sensitivity to block by class III antiarrhythmic agents. J Gen Physiol. 1990 Jul;96(1):195–215. doi: 10.1085/jgp.96.1.195. [DOI] [PMC free article] [PubMed] [Google Scholar]
  65. Schott J. J., Charpentier F., Peltier S., Foley P., Drouin E., Bouhour J. B., Donnelly P., Vergnaud G., Bachner L., Moisan J. P. Mapping of a gene for long QT syndrome to chromosome 4q25-27. Am J Hum Genet. 1995 Nov;57(5):1114–1122. [PMC free article] [PubMed] [Google Scholar]
  66. Schwartz P. J., Priori S. G., Locati E. H., Napolitano C., Cantù F., Towbin J. A., Keating M. T., Hammoude H., Brown A. M., Chen L. S. Long QT syndrome patients with mutations of the SCN5A and HERG genes have differential responses to Na+ channel blockade and to increases in heart rate. Implications for gene-specific therapy. Circulation. 1995 Dec 15;92(12):3381–3386. doi: 10.1161/01.cir.92.12.3381. [DOI] [PubMed] [Google Scholar]
  67. Shenasa M., Fromer M., Faugere G., Nadeau R., Leblanc R. A., Lambert C., Sadr-Ameli M. A. Efficacy and safety of intravenous and oral diltiazem for Wolff-Parkinson-White syndrome. Am J Cardiol. 1987 Feb 1;59(4):301–306. doi: 10.1016/0002-9149(87)90803-4. [DOI] [PubMed] [Google Scholar]
  68. Shimoni Y., Clark R. B., Giles W. R. Role of an inwardly rectifying potassium current in rabbit ventricular action potential. J Physiol. 1992 Mar;448:709–727. doi: 10.1113/jphysiol.1992.sp019066. [DOI] [PMC free article] [PubMed] [Google Scholar]
  69. Singh B. N., Hauswirth O. Comparative mechanisms of action of antiarrhythmic drugs. Am Heart J. 1974 Mar;87(3):367–382. doi: 10.1016/0002-8703(74)90080-5. [DOI] [PubMed] [Google Scholar]
  70. Snyders J., Knoth K. M., Roberds S. L., Tamkun M. M. Time-, voltage-, and state-dependent block by quinidine of a cloned human cardiac potassium channel. Mol Pharmacol. 1992 Feb;41(2):322–330. [PubMed] [Google Scholar]
  71. Splawski I., Tristani-Firouzi M., Lehmann M. H., Sanguinetti M. C., Keating M. T. Mutations in the hminK gene cause long QT syndrome and suppress IKs function. Nat Genet. 1997 Nov;17(3):338–340. doi: 10.1038/ng1197-338. [DOI] [PubMed] [Google Scholar]
  72. Sunami A., Fan Z., Sawanobori T., Hiraoka M. Use-dependent block of Na+ currents by mexiletine at the single channel level in guinea-pig ventricular myocytes. Br J Pharmacol. 1993 Sep;110(1):183–192. doi: 10.1111/j.1476-5381.1993.tb13790.x. [DOI] [PMC free article] [PubMed] [Google Scholar]
  73. Thomas S. H. Drugs, QT interval abnormalities and ventricular arrhythmias. Adverse Drug React Toxicol Rev. 1994 Summer;13(2):77–102. [PubMed] [Google Scholar]
  74. Till J., Shinebourne E. A., Rigby M. L., Clarke B., Ward D. E., Rowland E. Efficacy and safety of adenosine in the treatment of supraventricular tachycardia in infants and children. Br Heart J. 1989 Sep;62(3):204–211. doi: 10.1136/hrt.62.3.204. [DOI] [PMC free article] [PubMed] [Google Scholar]
  75. Vaughan Williams E. M. A classification of antiarrhythmic actions reassessed after a decade of new drugs. J Clin Pharmacol. 1984 Apr;24(4):129–147. doi: 10.1002/j.1552-4604.1984.tb01822.x. [DOI] [PubMed] [Google Scholar]
  76. Vincent G. M. The molecular genetics of the long QT syndrome: genes causing fainting and sudden death. Annu Rev Med. 1998;49:263–274. doi: 10.1146/annurev.med.49.1.263. [DOI] [PubMed] [Google Scholar]
  77. Virág L., Varró A., Papp J. G. Effect of disopyramide on potassium currents in rabbit ventricular myocytes. Naunyn Schmiedebergs Arch Pharmacol. 1998 Mar;357(3):268–275. doi: 10.1007/pl00005167. [DOI] [PubMed] [Google Scholar]
  78. Waldo A. L., Camm A. J., deRuyter H., Friedman P. L., MacNeil D. J., Pauls J. F., Pitt B., Pratt C. M., Schwartz P. J., Veltri E. P. Effect of d-sotalol on mortality in patients with left ventricular dysfunction after recent and remote myocardial infarction. The SWORD Investigators. Survival With Oral d-Sotalol. Lancet. 1996 Jul 6;348(9019):7–12. doi: 10.1016/s0140-6736(96)02149-6. [DOI] [PubMed] [Google Scholar]
  79. Wang D., Shryock J. C., Belardinelli L. Cellular basis for the negative dromotropic effect of adenosine on rabbit single atrioventricular nodal cells. Circ Res. 1996 Apr;78(4):697–706. doi: 10.1161/01.res.78.4.697. [DOI] [PubMed] [Google Scholar]
  80. Wang Q., Curran M. E., Splawski I., Burn T. C., Millholland J. M., VanRaay T. J., Shen J., Timothy K. W., Vincent G. M., de Jager T. Positional cloning of a novel potassium channel gene: KVLQT1 mutations cause cardiac arrhythmias. Nat Genet. 1996 Jan;12(1):17–23. doi: 10.1038/ng0196-17. [DOI] [PubMed] [Google Scholar]
  81. Wang Q., Shen J., Li Z., Timothy K., Vincent G. M., Priori S. G., Schwartz P. J., Keating M. T. Cardiac sodium channel mutations in patients with long QT syndrome, an inherited cardiac arrhythmia. Hum Mol Genet. 1995 Sep;4(9):1603–1607. doi: 10.1093/hmg/4.9.1603. [DOI] [PubMed] [Google Scholar]
  82. Wang Q., Shen J., Splawski I., Atkinson D., Li Z., Robinson J. L., Moss A. J., Towbin J. A., Keating M. T. SCN5A mutations associated with an inherited cardiac arrhythmia, long QT syndrome. Cell. 1995 Mar 10;80(5):805–811. doi: 10.1016/0092-8674(95)90359-3. [DOI] [PubMed] [Google Scholar]
  83. Welker H. A., Wiltshire H., Bullingham R. Clinical pharmacokinetics of mibefradil. Clin Pharmacokinet. 1998 Dec;35(6):405–423. doi: 10.2165/00003088-199835060-00001. [DOI] [PubMed] [Google Scholar]
  84. Wellens H. J., Tan S. L., Bär F. W., Düren D. R., Lie K. I., Dohmen H. M. Effect of verapamil studied by programmed electrical stimulation of the heart in patients with paroxysmal re-entrant supraventricular tachycardia. Br Heart J. 1977 Oct;39(10):1058–1066. doi: 10.1136/hrt.39.10.1058. [DOI] [PMC free article] [PubMed] [Google Scholar]
  85. Yue L., Feng J., Li G. R., Nattel S. Characterization of an ultrarapid delayed rectifier potassium channel involved in canine atrial repolarization. J Physiol. 1996 Nov 1;496(Pt 3):647–662. doi: 10.1113/jphysiol.1996.sp021716. [DOI] [PMC free article] [PubMed] [Google Scholar]
  86. Zipes D. P., Mendez C. Action of manganese ions and tetrodotoxin on atrioventricular nodal transmembrane potentials in isolated rabbit hearts. Circ Res. 1973 Apr;32(4):447–454. doi: 10.1161/01.res.32.4.447. [DOI] [PubMed] [Google Scholar]
  87. diMarco J. P., Sellers T. D., Lerman B. B., Greenberg M. L., Berne R. M., Belardinelli L. Diagnostic and therapeutic use of adenosine in patients with supraventricular tachyarrhythmias. J Am Coll Cardiol. 1985 Aug;6(2):417–425. doi: 10.1016/s0735-1097(85)80181-9. [DOI] [PubMed] [Google Scholar]
  88. van der Velden H. M., van Kempen M. J., Wijffels M. C., van Zijverden M., Groenewegen W. A., Allessie M. A., Jongsma H. J. Altered pattern of connexin40 distribution in persistent atrial fibrillation in the goat. J Cardiovasc Electrophysiol. 1998 Jun;9(6):596–607. doi: 10.1111/j.1540-8167.1998.tb00940.x. [DOI] [PubMed] [Google Scholar]

Articles from Heart are provided here courtesy of BMJ Publishing Group

RESOURCES